Euro Commission launches study into counterfeiting and parallel trade
This article was originally published in Clinica
The European Commission has told Clinica that there could be some tightening of the medical device regulatory framework to cope with the adverse effects of parallel trade. It has just launched a study that will focus on parallel trade at the same just as the study on combating counterfeit medical devices, anticipated at this time.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.